Harvard T.H. Chan School of Public Health
Human papillomavirus (HPV)-associated cancers occur more
frequently, and sometimes with more deadly consequences, among Hispanics,
blacks, and American Indian and Alaska Natives than among whites.
A new study
from Harvard T.H. Chan School of Public Health finds that HPV vaccination is
expected to reduce the cancer burden across all racial/ethnic groups.
However,
some disparities in cancer burden may persist and widen in the years to come if
their causes--such as lack of access to diagnoses and treatment--aren't
addressed.
The study will appear online April 28, 2016 in the journal Cancer.
"As expected, we found HPV vaccination would reduce the
overall disease burden for all racial and ethnic groups. However, we also found
that some racial and ethnic disparities may continue to exist," said Emily
Burger, postdoctoral research fellow at Harvard Chan School's Center for Health
Decision Science.
Nearly 80 million people in the U.S.--about one in four--are
currently infected with HPV. Roughly 14 million more become infected each year.
HPV infections that don't go away can lead to various forms of cancer.
HPV vaccines, licensed since 2006 and recommended for boys and girls, are expected to lead to declines in six HPV-associated cancers, including cervical, anal, and oropharyngeal (throat) cancers.
A recently licensed 9-valent HPV vaccine is
expected to protect against additional HPV types that cause cancer. HPV
vaccination has the potential to prevent up to three out of four HPV-associated
cancers.
But, so far, uptake of the vaccines has been slow. Recent data
from the Centers for Disease Control and Prevention (CDC) show that less than
half of girls--and even fewer boys--aged 13-17 years have received all three
recommended doses of the HPV vaccine series.
The number of young people who
complete the series also differs by racial and ethnic group. By comparison, the
vaccination rate for the adolescent Tdap vaccine (for protection against
tetanus, diphtheria and whooping cough) is about 85% or higher for all racial
and ethnic groups.
Partnering with experts from the CDC, the Harvard Chan
researchers used mathematical modeling to simulate the impact of alternative
HPV vaccine coverage scenarios on six HPV-associated cancers for different
racial/ethnic groups.
They took into account current cancer incidence rates,
and survival probabilities; the proportion of cancers due to HPV; and current
HPV vaccination rates by age, sex, race, and ethnicity.
The study used both absolute and relative measures to examine
the impact of HPV vaccination on racial/ethnic disparities.
They found that
while the absolute burden of cancer and disparities are expected to decrease
with current or improved HPV vaccination coverage, relative disparities may
persist and in some cases, increase.
For instance, with high uptake of the
9-valent HPV vaccine, the risk of dying from an HPV-associated cancer was
expected to decrease by 60% among all men.
The estimated decrease in cancer
burden was greater among some racial/ethnic groups, which led to an increase in
the relative disparity among men.
This is partly because HPV causes a smaller
proportion of oropharyngeal cancers in black males than in white males, so
vaccination would not have as much of an impact of the overall cancer burden
for that group.
"Our findings show that vaccination can lead to a dramatic
decrease in HPV-associated cancer in all racial and ethnic groups, but HPV
vaccination alone will not eliminate existing HPV-associated cancer
disparities. Efforts to improve HPV vaccination uptake in the U.S. must also be
accompanied by efforts to minimize differences in access to screening for
cervical cancer and access to timely diagnoses and treatment for all
HPV-associated cancers," said senior author Jane Kim, associate professor
of health decision science in the Department of Health Policy and Management.
